Our guidelines ensure our approach to working with pharmaceutical companies is transparent and cannot compromise our independence. We will not engage with any companies unless they contractually agree to these guidelines and do not restrict in any way what we communicate with our stakeholders and the public.
Our relationship with pharmaceutical companies is based on these principles:
- Working with pharmaceutical companies does not lead to automatic endorsement of the company or its products.
- Pharmaceutical companies have no input to the design or content of any Stroke Association branded programme, project or campaign.
- The Stroke Association and pharmaceutical companies will comply with relevant best practice guidelines and adhere to codes that have been put in place to ensure a clear, transparent and honest working relationship between pharmaceutical companies and the charitable sector, such as those produced by the Medicines and Healthcare products Regulatory Agency (MHRA), the Association of the British Pharmaceutical Industry (ABPI), the Fundraising Standards Board (FSB) and the Institute of Fundraising’s Codes of Practice.
- The Stroke Association is transparent about any financial support it receives and will ensure that agreements comply with both the regulatory requirements and our own guidelines.
We are proud to have successful partnerships with Boehringer Ingelheim, Ipsen, Pfizer/BMS Alliance, Bayer PLC, The Medtronic Foundation, Fresenius Kabi and Allergan.
Our work with Fresenius Kabi
Fresenius Kabi is a global health care company that specialises in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.
Fresenius Kabi sponsor our publication on problems with swallowing, enabling us to print and distribute to stroke survivors that develop this problem as a result of their stroke. Almost half of all stroke survivors will experience difficulties swallowing in the first few weeks after a stroke and for some this will be a long term issue.